Insulet Corporation (PODD), a medical device company, on Wednesday reported significantly higher first-quarter profit, driven by strong revenue growth, and raised its full-year sales outlook. Shares were up more than 3% in pre-market trading.
Net income more than doubled to $91.1 million, or $1.30 per share, from $35.4 million, or $0.50 per share, in the prior year
Excluding one-time items, adjusted earnings were $99.8 million, or $1.42 per share.
Operating income rose to $122.1 million from $88.8 million last year.
Adjusted operating income was $133.5 million.
Revenue jumped 33.9% to $761.7 million, or 30.1% in constant currency, exceeding the high end of the company's guidance range of 25% to 27% growth at constant currency rates.
For the full year, Insulet now expects revenue to grow 21% - 23% at constant currency, up from its prior outlook of 20% - 22%, and projects adjusted EPS growth of more than 25%.
For the second quarter, revenue is expected to grow 20% to 22%.
Insulet shares closed at $167.53 on Tuesday, down 2.25%.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.